Companies
AstraZeneca
Clinical pipelines — Accelerated trials.
- Country
- United Kingdom
Coverage
| CN | EU | US | |
|---|---|---|---|
| finance-investment | ✓ | ✓ | ✓ |
| therapeutics-platforms | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Verifiable facts
| Fact | Value | Source |
|---|---|---|
| Funding | CSPC Pharmaceuticals collaboration $4.7bn upfront and milestone payments | proactiveinvestors.co.uk |
| Capacity | Macclesfield site: 72 million packs of medicine; Liverpool site: 20 million vaccine doses annually | careers.astrazeneca.com |
| Regulatory approval | 43 regulatory approvals in major markets in FY 2025; 8 first approvals in H1 2026; 30 approvals in major regions since Q4 2025 results | astrazeneca.com · proactiveinvestors.co.uk |
| Production site | Macclesfield (pharmaceutical manufacturing), Speke (biologics), and Liverpool (vaccines) | careers.astrazeneca.com |
| Headcount | Approximately 10,000 employees in the UK | careers.astrazeneca.com · astrazeneca.co.uk |
| Revenue | Total Revenue $58.7 billion for FY 2025; $30.672 billion for H1 2026 | astrazeneca.com · proactiveinvestors.co.uk |
Independent sources: proactiveinvestors.co.uk
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Antibody-drug conjugates (ADCs) | therapeutics-platforms | High | → |
| Corporate biotech accelerators (JLABS, Bayer CoLaborator) | finance-investment | Medium | → |
Compiled by BIOECON from primary sources.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.